Epidrug modulated expression of MiR‌-152 and MiR-148a reverse cisplatin resistance in ovarian cancer cells: an experimental in vitro study

Document Type : Research article


1 Department of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

2 Department of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.Motherand Newborn Health Research Center,Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

3 Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences,Yazd, Iran.


Cisplatin is a common agent which is used to treat Epithelial Ovarian Cancer (EOC), but cisplatin resistance is a major obstacle in successful treatment of ovarian cancer. Aberration in epigenetic changes play an important role in disregulation of gene expression. MiR-152 and miR-148a are frequently down-regulated in EOC due to promoter hyper-methylation. DNA methyltransferase1 (DNMT1), the main enzyme in maintenance of the pattern of DNA methylation, is one of the targets of miR-152 and miR-148a. Aberrantly up-regulation of DNMT1 is responsible for silencing of tumor suppressor genes in carcinogenesis. We hypothesized that re-expression of miR-152 and miR-148a and consequently down-regulation of DNMT1 may resensitize cancerous cells to chemotherapeutics agents. The aim of the present study is to investigate the effect of 5-azacytidine (5-Aza) and Trichostatin A on miR-152 and miR-148a expression in A2780CP ovarian cancer cell line. Optimal doses of 5-Azacitidine and TSA were measured by 3-(4,5-dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A2780CP cell line was treated by each drugs, alone or in combination and the expression of miR-148a, miR-152 and DNMT1 was evaluated by Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR). The results revealed that TSA and 5-Azacytidine are able to revive the expression of miR-148a and miR-152 genes and mediate growth inhibition of epithelial ovarian cancer cells. The present study suggests that re-expression of miR-148a and miR-152 by epigenetic therapy aiming to DNMT1 suppression might resensitize resistant ovarian tumors to conventional chemotherapy.

Graphical Abstract

Epidrug modulated expression of MiR‌-152 and MiR-148a reverse cisplatin resistance in ovarian cancer cells: an experimental in vitro study


1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun M. Cancer statistics. CA:Cancer J.Clin. )2009( 59: 225-49.
2. Kamali M, Hamadani S, Neamatzadeh H, Mazaheri M, Shehneh MZ, Gilani MM and Haghighi F. Association of XRCC2 rs3218536 polymorphism with susceptibility of breast and ovarian cancer: a systematic review and meta-analysis. Asian Pac. J. Cancer Prev. )2017( 18: 1743-49.
3. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. )2004( 351: 2519-29.
4. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, D Etemadmoghadam, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD and Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer. )2011( 11: 719-25.
5. Liu X, Chan D and Ngan H. Mechanisms of chemoresistance in human ovarian cancer at a glance. Gynecol. Obstet. )2012( 2: 100−104.
6. Balch C, Huang TH-M, Brown R and Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol. )2004( 191: 1552-72.
7. Hatziapostolou M and Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell. Mol. Life Sci. )2011( 68: 1681-702.
8.Balch C, Fang F, Matei DE, Huang TH-M and Nephew KP. Minireview: epigenetic changes in ovarian cancer.  J. Endocrinol. )2009( 150: 4003-11.
9.Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S and Nephew KP. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med. Genomics. )2009( 2: 34.
10.Gadducci A, Sergiampietri C, Lanfredini N and Guiggi I. Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecol. Endocrinol. )2014( 30: 266-71.
11. Zhou X, Zhao F, Wang Z-N, Song Y-X, Chang H, Chiang Y and Xu H. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol. Rep. )2012( 27:447-54.
12. Liu X, Li J, Qin F and Dai S. miR-152 as a tumor suppressor microRNA: Target recognition and regulation in cancer. Oncol Lett. )2016( 11: 3911-16.
13.Chen Y, Song Y-X and Wang Z-N. The microRNA-148/152 family: multi-faceted players. Mol. Cancer )2013( 12: 43.
14.Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, Li F, Han D, Wang L, Zhang G and Gao X. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene )2014( 33: 378-86.
15.Thurn KT, Thomas S, Moore A and Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. )2011( 7: 263-83.
16.Xu Y, Chao L, Wang J and Sun Y. miRNA‑148a regulates the expression of the estrogen receptor through DNMT1‑mediated DNA methylation in breast cancer cells. Oncol Lett. )2017( 14: 4736-40.
17.Dasari S and Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. .Eur. J. Pharmacol. )2014( 740: 364-78.
18.Vargas AN. Natural history of ovarian cancer. Ecancermedicalscience )2014( 8: 465.
19.Stresemann C and Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer. )2008( 123: 8-13.
20.Vanhaecke T, Papeleu P, Elaut G and Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem. )2004( 11: 1629-43.
21.Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. )1999( 9: 40-8.
22. Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, Ferrandina G, Costanzo A and Tuosto L. Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol. Cancer Ther. )2008( 7: 1410-19.
23.Chen P-S, Su J-L and Hung M-C. Dysregulation of microRNAs in cancer. J. Biomed. Sci. )2012( 19: 90.
24.Magee P, Shi L and Garofalo M. Role of microRNAs in chemoresistance. Ann. Transl. Med. )2015( 3: 332.
25.Chen S, Jiao J-W, Sun K-X, Zong Z-H and Zhao Y. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Dev. Ther. )2015( 9: 5225-35.
26.Li X, Chen W, Jin Y, Xue R, Su J, Mu Z, Li J and Jiang S. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Biochem. Pharmacol. )2019( 161: 98-112.
27.Li Y, Deng X, Zeng X and Peng X. The role of Mir-148a in cancer. J. Cancer) 2016( 7: 1233-41.
28.Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C and Liu Z. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J. Gastrointest. Surg. )2010( 14: 1170-9.
29.Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y, Qi YT, Xu Q, Li W, Lu B, Peiper SS, Jiang BH and Liu LZ. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J. Mol. Cell Biol. )2013( 5: 3-13.
30.Yan B, Yin F, Wang Q, Zhang W and Li L. Integration and bioinformatics analysis of DNA‑methylated genes associated with drug resistance in ovarian cancer. Oncol. Lett. )2016( 12: 157-66.
31. Cedar H and Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. )2009( 10: 295-304.
32.Cacan E, Ali MW, Boyd NH, Hooks SB and Greer SF. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS One )2014( 9: e87455.
33.Zhang W, Chen J-H, Shan T, Aguilera-Barrantes I, Wang L-S, Huang TH-M, Rader JS, Sheng X and Huang YW. miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. Lab. Invest. )2018( 98: 1397-407.
34.Liu Y, Song N, Ren K, Meng S, Xie Y, Long Q, Chen X and Zhao X. Expression loss and revivification of RhoB gene in 35.Sanaei M and Kavoosi F. Effect of 5-aza-2'-deoxycytidine in comparison to valproic acid and trichostatin A on histone deacetylase 1, DNA methyltransferase 1, and CIP/KIP family (p21, p27, and p57) genes expression, cell growth inhibition, and apoptosis induction in colon cancer SW480 cell line. Adv. Biomed. Res. )2019( 8.
36.Watson RE, Curtin GM, Hellmann GM, Doolittle DJ and Goodman JI. Increased DNA methylation in the HoxA5 promoter region correlates with decreased expression of the gene during tumor promotion. Mol. Carcinog. )2004( 41: 54-66.
37.Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG and Brock MV. Hypermethylation of the GATA genes in lung cancer. Clin. Cancer Res. )2004( 10: 7917-24.
38. Moufarrij S, Srivastava A, Gomez S, Hadley M, Palmer E, Austin PT, Chisholm S, Roche K, Yu A, Li J, Zhu W, Lopez-Acevedo M, Villagra A and Chiappinelli KB. Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer. Sci. Rep. )2020( 10: 1-12.